Safety and Efficacy Assessment of Diagnostic Microprobe (inPROBE) in Women at High Risk of Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05415943|
Recruitment Status : Completed
First Posted : June 13, 2022
Last Update Posted : March 9, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Device: Diagnostic microprobe (inPROBE) medical device||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||18 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-label, Multicentre, Single-arm Safety and Efficacy Clinical Investigation of Diagnostic Microprobe (inPROBE) for the Assessment of HER2 Receptor Expression in Population of Women at High Risk of Breast Cancer|
|Actual Study Start Date :||August 24, 2022|
|Actual Primary Completion Date :||March 2, 2023|
|Actual Study Completion Date :||March 2, 2023|
Experimental: Women at high risk of breast cancer
Women with a confirmed diagnosis of breast cancer by thick-needle biopsy and known HER2 receptor expression status, referred for surgical treatment.
Device: Diagnostic microprobe (inPROBE) medical device
Introduction of the inPROBE microprobe (two simultaneous punctures) into the breast as a procedure prior to surgical resection of tumors with known HER2 receptor status.
- Preliminary determination of HER2 receptor concentration ranges detected with inPROBE corresponding to HER2 receptor status (positive/negative) as determined by current diagnostic standard (IHC/FISH). [ Time Frame: Day 1 ]
- The occurrence of defects, failures, and fractures of the inPROBE probe during the diagnostic procedure leading to AE/ SAE. [ Time Frame: Day 1 - Day 14 ]
- Comparison of the correlation of HER2 receptor concentrations detected by the inPROBE probe located in the tumor and in the immediate tumor area in HER2 positive patients. [ Time Frame: Day 1 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 75 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||No|
- Provision of written informed consent to participate in the clinical investigation;
- Female patient aged ≥ 18 to ≤ 75 years;
- The patient's overall health status as determined by Eastern Cooperative Oncology Group (ECOG) from 0 to 1;
- Preserved full ability to communicate with the investigator and to understand and comply with the requirements of the Clinical investigation plan;
- High likelihood of attending follow-up appointments in accordance with the study design and completing this study in accordance with this Clinical investigation plan.
- The presence of a malignant neoplasm (breast cancer) confirmed by histopathologic examination of material from a gross needle biopsy of the tumor, with specific HER2 receptor status.
- Patient referred for surgical treatment of breast cancer.
- History of treatment with trastuzumab, or other HER 2 receptor-binding antibody, as part of neoadjuvant (induction) therapy for currently diagnosed and treated breast cancer.
- A skin disorder that prevents or contraindicates to perform a probe examination in the opinion of the investigator;
- Breast inflammation/infection on the day of the probe examination;
- Allergy to any component of the medical device that is the subject of this clinical investigation;
- An implant in the breast where the inPROBE study and surgery will be performed;
- Any physical or psychiatric condition, or laboratory test values outside the normal range, which in the opinion of the investigator constitute a contraindication to the patient's participation in this clinical investigation or pose a risk of exclusion from the study or premature termination of participation in the study;
- Any clinically significant abnormality in physical examination, vital signs, or laboratory tests that, in the opinion of the investigator, is a contraindication to participation in this clinical trial;
- Pregnancy or breastfeeding;
- Participation in another clinical trial within 30 days prior to signing informed consent to participate in this clinical investigation;
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05415943
|Uniwersyteckie Centrum Leczenia Chorób Piersi, Szpital Uniwersytecki w Krakowie|
|Kraków, Poland, 30-688|
|Klinika Chirurgii Onkologicznej|
|Lublin, Poland, 20-081|
|Responsible Party:||SDS Optic S.A.|
|Other Study ID Numbers:||
|First Posted:||June 13, 2022 Key Record Dates|
|Last Update Posted:||March 9, 2023|
|Last Verified:||March 2023|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Neoplasms by Site